Whist Subholdings
VC Fund
Whist Subholdings is a venture capital investment firm.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Whist Subholdings invests in
Stages Whist Subholdings invests in
Countries Whist Subholdings invests in
Investment Focus
Industry
- Medical 1 (50%)
- Agriculture 1 (50%)
- Health Care 1 (50%)
- Biotechnology 1 (50%)
- Meat and Poultry 1 (50%)
Stage
- Seed 1 (50%)
- Venture - Series Unknown 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Pacific GeneTech
|
Pacific GeneTech develops and commercializes first-in-class or best-in-class vaccines for areas of high unmet or underserved needs in food safety and livestock animal health. The global animal vaccine market is a valuable opportunity and is expected to reach US$20.6 billion by 2021. Livestock illness can lead to human infections, poor feedconversion, or loss of animals, making it a significant economic burden to producers.Founded in 2009, Pacific GeneTech focuses on developing and commercializing vaccines for the livestock industry through their proprietary Aegis platform which have broad cross-protection. In 2012, they acquired the exclusive global rights to Hercules Adjuvant Delivery System to enhance Aegis developed vaccines and explore partnership opportunities for other vaccine products. Pacific GeneTech has out-licensed two of its leading poultry vaccines addressing economically important gastro-intestinal pathogens and has out-licensed its Hercules adjuvant for use in third-party vaccines. Vaccines for other pathogens and animal species are under development. Pacific GeneTech is developing other applications for its Hercules adjuvant delivery system. Pacific GeneTech, through its affiliate company, PGTx, has commenced programs with collaborators addressing human dysentery. | $10M / Venture - Series Unknown / Aug 24, 2022 | |
|
Pacific GeneTech
|
Pacific GeneTech develops and commercializes first-in-class or best-in-class vaccines for areas of high unmet or underserved needs in food safety and livestock animal health. The global animal vaccine market is a valuable opportunity and is expected to reach US$20.6 billion by 2021. Livestock illness can lead to human infections, poor feedconversion, or loss of animals, making it a significant economic burden to producers.Founded in 2009, Pacific GeneTech focuses on developing and commercializing vaccines for the livestock industry through their proprietary Aegis platform which have broad cross-protection. In 2012, they acquired the exclusive global rights to Hercules Adjuvant Delivery System to enhance Aegis developed vaccines and explore partnership opportunities for other vaccine products. Pacific GeneTech has out-licensed two of its leading poultry vaccines addressing economically important gastro-intestinal pathogens and has out-licensed its Hercules adjuvant for use in third-party vaccines. Vaccines for other pathogens and animal species are under development. Pacific GeneTech is developing other applications for its Hercules adjuvant delivery system. Pacific GeneTech, through its affiliate company, PGTx, has commenced programs with collaborators addressing human dysentery. | $10M / Seed / Aug 24, 2022 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Whist Subholdings invest in?
Whist Subholdings invests primarily in Medical, Agriculture and Health Care startups, most often at Seed and Venture - Series Unknown stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Whist Subholdings last invest?
The most recent investment recorded for Whist Subholdings closed in Aug 2022. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
